Sugi Predict

Sugi Predict / Targets / ACVR1B

ACVR1B

Activin receptor type-1B · P36896 · ACVR1B on Sugi Atlas →

20,092 patent compounds predicted against ACVR1B, 13,694 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL456393 SCHEMBL456393 1.00 14/20
SCHEMBL722250 SCHEMBL722250 0.46 5/20
SCHEMBL335755 SCHEMBL335755 0.59 4/20
SCHEMBL725247 SCHEMBL725247 0.45 4/20
SCHEMBL373422 SCHEMBL373422 1.00 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL140197) 0.98 3/20
SCHEMBL373248 SCHEMBL373248 0.74 3/20
SCHEMBL412135 SCHEMBL412135 0.55 3/20
SCHEMBL414478 SCHEMBL414478 0.53 3/20
SCHEMBL373361 SCHEMBL373361 0.51 3/20
SCHEMBL375120 SCHEMBL375120 0.40 3/20
Sb-431542 Sb-431542 (SCHEMBL310028) 1.00 2/20
SCHEMBL373558 SCHEMBL373558 1.00 2/20
Dorsomorphin Dorsomorphin (SCHEMBL463155) 1.00 2/20
Lestaurtinib Lestaurtinib (SCHEMBL730955) 1.00 2/20
SCHEMBL373737 SCHEMBL373737 0.89 2/20
Sb-431542 Sb-431542 (SCHEMBL155156) 0.85 2/20
SCHEMBL373802 SCHEMBL373802 0.71 2/20
SCHEMBL410420 SCHEMBL410420 0.67 2/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.67 2/20

Clinical trials — most relevant to ACVR1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) PHASE4COMPLETED
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor PHASE1/PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer PHASE2COMPLETED
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
The Use of Adhesion Molecule Loaded Hydrogel With Minimally Invasive Surgical Technique in Treatment of Periodontal Intrabony Defect PHASE1/PHASE2COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy PHASE1COMPLETED
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults PHASE1NOT_YET_RECRUITING
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension nanCOMPLETED
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension nanUNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia nanRECRUITING
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers nanCOMPLETED
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension. nanRECRUITING
StratosPHere (Non-interventional Study) nanCOMPLETED
C-Type Natriuretic Peptide and Achondroplasia nanCOMPLETED
Influence of Sarcopenia on the Course of the Diseases nanRECRUITING
Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital nanNOT_YET_RECRUITING
Luspatercept in Metastatic AGCT of the Ovary nanCOMPLETED
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals nanRECRUITING
National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension nanUNKNOWN
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension nanCOMPLETED
European Registry of Acutely Decompensated Pulmonary Arterial Hypertension nanNOT_YET_RECRUITING
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis nanUNKNOWN
Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension nanACTIVE_NOT_RECRUITING
The PAH Platform for Deep Phenotyping in Korean Subjects nanUNKNOWN
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ACVR1B binder may also engage these)

ProteinNameSimilarity
P80202 — 1.000 P80202 →
Q61271 — 1.000 Q61271 →
BMPR1B Bone morphogenetic protein receptor type-1B 1.000 landscape →
Q64729 — 1.000 Q64729 →
P80204 — 1.000 P80204 →
Q05438 — 1.000 Q05438 →
Q78EA7 — 1.000 Q78EA7 →
O46680 — 1.000 O46680 →
P70539 — 1.000 P70539 →
Q90ZK6 — 1.000 Q90ZK6 →
Q5CD18 — 0.999 Q5CD18 →
P80203 — 0.999 P80203 →
Q28041 — 0.999 Q28041 →
TGFBR1 TGF-beta receptor type-1 0.998 landscape →
P80201 — 0.997 P80201 →
P37172 — 0.996 P37172 →
P36895 — 0.996 P36895 →
Q8NER5 — 0.996 Q8NER5 →
Q61288 — 0.995 Q61288 →
Q8K348 — 0.995 Q8K348 →
P36898 — 0.993 P36898 →
Q5RAN0 — 0.992 Q5RAN0 →
Q24468 — 0.991 Q24468 →
BMPR1A Bone morphogenetic protein receptor type-1A 0.990 landscape →
P54757 — 0.989 P54757 →
Q60629 — 0.988 Q60629 →
ACVR1 Activin receptor type-1 0.988 landscape →
P54755 — 0.988 P54755 →
EPHA6 Ephrin type-A receptor 6 0.987 landscape →
EPHA5 Ephrin type-A receptor 5 0.987 landscape →